drugset / Trial / NCT00002420
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
Phase 2
Terminated
25 enrolled
Bristol-Myers Squibb
Pharmacia and Upjohn · collabTriangle Pharmaceuticals · collab
Open-labelTreatment
Summary
The purpose of this study is to see if it is safe and effective to give MKC-442, didanosine (ddI), stavudine (d4T), and delavirdine (DLV) to HIV-positive patients.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Delavirdine | Small molecule | — | — |
| Subject | Didanosine | Small molecule | — | — |
| Subject | Emivirine | Small molecule | — | — |
| Subject | Hydroxyurea | Other / unclassified | — | — |
| Subject | Stavudine | Other / unclassified | — | — |